It is widely used in children from 6 years of age with moderate-to-severe atopic dermatitis when topical therapies are insufficient or not recommended [146], because, in atopic dermatitis pathogenesis, IL-4 and IL-13 play a key role, decreasing the expression of genes that encode for important elements of the epidermal barrier [147]. This evidence concerns the gene IL13 and atopic eczema.